Chief Provincial Diagnostics Officer
Provincial Health Services Authority, Canada
Craig Ivany is a laboratory services strategist with over 35 years of experience influencing healthcare. His depth of practice includes a legacy of leadership across Canada. This includes VP roles with DynaLIFE Alberta and Dynacare Ontario, CEO of Eastern Ontario Regional Laboratory Association, President and CEO of Alberta Public Laboratories, and currently the Chief Provincial Diagnostics Officer, Provincial Health Services Authority, British Columbia. Craig is a certified health executive and long-standing member of the Canadian College of Health Leaders, holds an ICD.D with the Institute of Corporate Directors, and is an Adjunct Professor, Faculty of Medicine, University of British Columba.
Craig Ivany reported the following relevant financial disclosures:
• Board/Committee Membership/Advisory Board: Abbott – Univants of Healthcare and ELX; In Common Labs
What can be done today for a measurable change in healthcare delivery, outcomes and costs?
Professor of Pathology and Professor of Medical and Research Technology
University of Maryland School of Medicine, USA
Dr. Christenson is Professor of Pathology and Professor of Medical and Research Technology at the University of Maryland School of Medicine, Baltimore, Maryland USA. Clinically, he is Medical Director of the Core Laboratories and Point of Care Testing at the University of Maryland Medical Center. Academically, Prof. Christenson is a fellow of the AACC Academy and a fellow of the American College of Cardiology (ACC). He has promulgated over 400 peer-reviewed papers, 6 books, 34 textbook chapters and holds 4 patents. He is principal investigator of the Clinical Core Research Laboratory, which focuses on FDA and Government Clinical Trials. Prof. Christenson has long-standing interest in Evidence-Based Laboratory Medicine (EBLM) and chaired EBLM committees for both AACC and IFCC. Currently, an application of keen interest is using EBLM techniques for demonstrating the value of laboratory medicine. Dr. Christenson has been active in professional societies, including serving as president of the AACC, on the accreditation board of the ACC, and has held leadership positions with the IFCC.
Rob Christenson reported the following relevant financial disclosures:
• Consultant Fee: Becton Dickinson, Roche Diagnostics, Siemens Healthineers, Beckman Coulter, Quidel, Pixcell Medical, Sphingotech
• Board/Committee Membership/Advisory Board: Becton Dickinson, Roche Diagnostics, Siemens Healthineers, Beckman Coulter, Quidel, Pixcell Medical, Sphingotech
• Presenter/Speaker: Becton Dickinson, Roche Diagnostics, Siemens Healthineers, Beckman Coulter, Quidel, Pixcell Medical, Sphingotech
President, Executive Director
Project Santa Fe Foundation, USA
Lab 2.0 Strategic Services, USA
Khosrow Shotorbani is the CEO and founder of Lab 2.0 Strategic Services, LLC. He is a member of the board, and President, Executive Director of Project Santa Fe Foundation, advocating for Clinical Lab 2.0 movement.
Mr. Shotorbani was instrumental in the creation of Project Santa Fe—a initiative with like-minded executives—helping to drive new frontiers that will define future economic valuation and placement of diagnostic services and practice of laboratory medicine.
As the former President and Chief Executive Officer at TriCore Reference Laboratories, Mr. Shotorbani oversaw the corporate direction and strategy of TriCore, focusing on leadership, culture and innovation, as well as operations, growth, and the financial health of the company. He led TriCore’s initiatives based on the premise to improve health outcomes, population health and lower overall costs of delivery by predictive utilization of laboratory data.
Before joining TriCore in 2014, Mr. Shotorbani served as Senior Vice President, co-Director of Business Development and Director of Business Innovations at ARUP. He joined ARUP in 1984 as a medical technologist and while at ARUP advanced to positions with progressive responsibility over his 30-year tenure.
Khosrow Shotorbani reported no relevant financial disclosures.